Powell Annabel A, Costella Annastella, Roche Rachel, Leeman David, Brown Ashley, Emmanouil Beatrice, Gillyon-Powell Mark, Harris Ross, Mitchell Holly D, Simmons Ruth, Desai Monica
Blood Safety, Hepatitis, Sexually Transmitted Infections (STIs) and HIV Division, UK Health Security Agency, London, UK.
Department of Hepatology, Imperial College London, Imperial College NIHR BRC, London, UK.
J Viral Hepat. 2025 Apr;32(4):e70016. doi: 10.1111/jvh.70016.
The United Kingdom, along with many other countries, is working towards eliminating viral hepatitis as a public health threat by 2030, with a combined mortality target of less than or equal to six deaths per 100,000 population. The current methodology of reporting uses death registrations alone, which has been estimated to underestimate mortality rates by up to 60% for hepatitis C (HCV)-related liver disease. We aim to conduct a sensitivity analysis using data linkage of death certificates, hepatitis B (HBV) and HCV diagnoses and admissions for end-stage liver disease (ESLD) and/or hepatocellular carcinoma (HCC) to estimate mortality rates, assess progress towards elimination and evaluate underreporting. Between 2000 and 2023, 7967 deaths were reported due to HBV- and/or HCV-associated ESLD and/or HCC. Using data linkage of all three datasets, this increased to 11,487, with underreporting estimated to be 37% overall. The upper bound combined mortality rate was estimated to be 1.3 deaths per 100,000 population at its peak in 2015, therefore surpassing the WHO target for all years evaluated. From 2015 to 2023, both HCV-associated ESLD and/or HCC mortality decreased (1.12 to 0.88 deaths per 100,000 population), however, there was a slight increase for HBV-associated ESLD and/or HCC deaths during the same time frame (0.3 to 0.35). A higher proportion of HBV-related deaths were in males (p < 0.05) who died outside London (p < 0.05) and a lower proportion were White (p < 0.05) when compared to HCV-related deaths. While England has met the WHO impact targets, it is important we continue to drive reductions in mortality.
英国与许多其他国家一道,正努力到2030年消除病毒性肝炎这一公共卫生威胁,设定的综合死亡率目标为每10万人口死亡人数小于或等于6人。目前的报告方法仅使用死亡登记数据,据估计,这会使丙型肝炎(HCV)相关肝病的死亡率低估高达60%。我们旨在利用死亡证明、乙型肝炎(HBV)和HCV诊断以及终末期肝病(ESLD)和/或肝细胞癌(HCC)入院数据的关联进行敏感性分析,以估计死亡率、评估消除工作进展并评估报告不足情况。2000年至2023年期间,报告了7967例因HBV和/或HCV相关的ESLD和/或HCC导致的死亡。通过对所有三个数据集进行数据关联,这一数字增至11487例,总体报告不足估计为37%。2015年峰值时,上限综合死亡率估计为每10万人口1.3例死亡,因此在所有评估年份均超过了世界卫生组织的目标。2015年至2023年期间,HCV相关的ESLD和/或HCC死亡率均有所下降(从每10万人口1.12例降至0.88例),然而,同期HBV相关的ESLD和/或HCC死亡人数略有增加(从0.3例增至0.35例)。与HCV相关死亡相比,HBV相关死亡中男性比例更高(p<0.05),在伦敦以外地区死亡的比例更高(p<0.05),白人比例更低(p<0.05)。虽然英格兰已实现世界卫生组织的影响目标,但我们继续推动死亡率下降仍很重要。